Latest News and Press Releases
Want to stay updated on the latest news?
-
马萨诸塞州剑桥, May 22, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc.（“APRINOIA”或“公司”），专注于开发神经退行性疾病的新颖治疗和精确诊断方法的临床阶段生物制药公司，今天宣布，美国食品药品监督管理局（FDA）于2024年5月月8日授予正电子发射断层扫描（PET）示踪剂APN-1607（florzolotau...
-
マサチューセッツ州ケンブリッジ , May 22, 2024 (GLOBE NEWSWIRE) --...
-
麻塞諸塞州劍橋, May 22, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc.（“APRINOIA”或“公司”），以開發神經退行性疾病的新穎治療和精確診斷方法為主的臨床階段生物製藥公司，今天宣佈，美國食品藥品監督管理局（FDA）於2024年5月月8日授予正電子發射斷層掃描（PET）示蹤劑APN-1607（florzolotau...
-
CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision...
-
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“Aprinoia” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision...
-
Investment Supports APRINOIA’s Effort to Bring Precision Medicine to Neuroscience, Advancing APRINOIA’s Diagnostic and Therapeutic PipelinesFunding Supports APRINOIA’s Goal to Bring a Central Nervous...
-
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
-
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...